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Abstract: 
 
Purpose:  To assess the cosmetic impact of breast conserving surgery (BCS), whole breast 
irradiation (WBI) fractionation and tumour bed boost (TBB) use in a phase III trial for women 
with ductal carcinoma in situ (DCIS) of the breast. 
 
Materials and Methods:  Baseline and 3-year cosmesis were assessed using the European 
Organization for Research and Treatment of Cancer (EORTC) Cosmetic Rating System and digital 
images in a randomised trial of non-low risk DCIS treated with postoperative WBI +/- TBB.  
Baseline cosmesis was assessed for four geographic clusters of treating centres. Cosmetic 
failure was a global score of fair or poor.  Cosmetic deterioration was a score change from 
excellent or good at baseline to fair or poor at three years.  Odds ratios for cosmetic 
deterioration by WBI dose-fractionation and TBB use were calculated for both scoring systems. 
 
Results:  1608 women were enrolled from 11 countries between 2007 and 2014.  85-90% had 
excellent or good baseline cosmesis independent of geography or assessment method. TBB (16 
Gy in 8 fractions) was associated with a >2-fold risk of cosmetic deterioration (p<0.001). 
Hypofractionated WBI (42.5 Gy in 16 fractions) achieved statistically similar 3-year cosmesis 
compared to conventional WBI (50 Gy in 25 fractions) (p≥0.18). The adverse impact of a TBB 
was not significantly associated with WBI fractionation (interaction p≥0.30).  
 
Conclusions:  Cosmetic failure from BCS was similar across international jurisdictions.  A TBB of 
16 Gy increased the rate of cosmetic deterioration. Hypofractionated WBI achieved similar 3-
year cosmesis as conventional WBI in women treated with BCS for DCIS.  
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Introduction 
 
Breast conserving surgery (BCS) followed by radiation therapy (RT) is the primary management for many 
women with early-stage, invasive breast cancer and ductal carcinoma in situ (DCIS).[1-4]  Most women 
achieve good to excellent cosmesis after BCS and RT but some experience cosmetic failure, defined as 
fair or poor cosmetic outcomes.[5-17]  However, comparisons of cosmetic outcomes across 
international jurisdictions using contemporary surgical and RT techniques for DCIS are lacking. 
 
Between 2007 and 2014, in collaboration with the Breast International Group (BIG), the Trans-Tasman 
Radiation Oncology Group (TROG) coordinated a randomised, phase III trial of tumour bed boost (TBB) 
following conventionally fractionated or hypofractionated whole breast irradiation (WBI) for women 
with non-low risk, unilateral, DCIS of the breast treated with BCS (BIG 03-07/TROG 07.01 trial, 
Clinicaltrials.gov registration number: NCT00470236). The trial was a collaboration of seven clinical trials 
organisations across four continents.  As part of the trial, cosmetic outcomes were evaluated using the 
validated European Organisation for Research and Treatment of Cancer (EORTC) Cosmetic Rating 
System,[5] and standardised clinical photographs were obtained at baseline (after BCS; prior to RT) and 
at protocol-specified intervals after RT.   
 
This is a report of an international comparison of cosmetic outcomes at baseline after BCS, and at three 
years after post-operative WBI with or without a TBB, based on prospective cosmetic assessments and 
central review of standardised clinical photographs within the BIG 03-07/TROG 07.01 trial.    
 
 
Materials and Methods 
 
Treatments on the BIG 03-07/TROG 07.01 trial 
The BIG 03-07/TROG 07.01 trial enrolled women aged ≥ 18 years with unilateral, non-low risk (Appendix 
B) DCIS treated by BCS with ≥ one mm clear radial margins, who were suitable for post-operative RT and 
available for long-term follow up.   
 
Women were randomised, 1:1, to receive a TBB of 16 Gy in 8 fractions or no TBB following WBI. The 
permitted WBI schedules were 50 Gy in 25 fractions (conventional fractionation) or 42.5 Gy in 16 
fractions (hypofractionation). Each centre, prior to entering their first patient on study, elected to use 
one of the WBI regimens or participate in a secondary randomisation between the two regimens.  
Stratification factors were age (< 50, ≥50), planned endocrine therapy use (yes, no) and treating centre. 
 
Computer tomography (CT)-based RT planning was mandatory.  The TBB dose was delivered to the 
primary site with a protocol-defined margin using an incident electron beam or megavoltage photons via 
tangential or other field arrangements that conformed to the dose homogeneity and normal tissue 
constraints of the protocol.  Interstitial brachytherapy was not permitted. The WBI was delivered using 
tangential 4-18MV photon beams with wedges or sub-fields to optimise homogeneity.  A point dose 
>110% (to a volume of 2cc) was a protocol deviation.  RT commenced within 12 weeks of the last breast 
surgical procedure and was delivered once daily.  The number of treatment visits required of patients 
ranged from 16 (hypofractionated WBI, no TBB) to 33 (conventionally fractionated WBI plus TBB). 
Adjuvant endocrine therapy use was at the discretion of the treating physicians. Chemotherapy was 
prohibited.  Table 1 shows the distributions of baseline patient characteristics, geographic regions and 
treatments.   
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Cosmetic scoring by treatment centres 
Following BCS and prior to randomisation, treatment centre staff completed baseline cosmetic 
assessments using the 10-part EORTC Cosmetic Rating System which compared the treated and 
untreated breasts for size and shape, nipple/areolar location and shape, visibility of surgical scar(s), skin 
colour and the extent of breast oedema or skin telangiectasia (Appendix C).[18] A global cosmetic score, 
categorised as excellent, good, fair or poor was assigned.  At baseline, the cosmetic score was a measure 
of the impact of BCS alone. Cosmetic scores were recorded prospectively to assess the impact of both 
surgery and RT, at one, three and five years after RT.  Baseline and 3-year global cosmetic scores were 
used in the current study. 
 
Cosmetic scoring from clinical digital images  
To complement subjective assessments, standardised digital images of the breasts (Appendix D) were 
obtained and submitted electronically to the TROG database.  In other studies, panels of 3-5 
experienced clinicians have scored cosmesis from photographs or digital images and average or 
consensus scores were calculated and used.[8,11,12,14]  There would have been considerable logistical 
challenges in this international trial to assemble, train, demonstrate consistency between, and convene 
panels in different countries to review 500-1000 digital images each in a timely manner.  Similarly, 
retrospectively digitizing nearly 3000 images for use in the BCCT.core system was not felt to be practical.  
Thus, for the current study, one radiation oncologist experienced in breast cosmetic evaluation (IAO) 
scored all the baseline and 3-year post-RT digital images in the trial database as of February 16, 2018. 
Electronic files of digital images, blinded for patient identifiers, timing (baseline vs. 3 years post RT), 
treatment centre geographic region, WBI dose-fractionation and TBB use, were created by TROG trial 
centre staff in Newcastle, Australia, and sent to the reviewer in Calgary, Canada.  Visible scars enabled 
the reviewer to identify treatment laterality in most cases.   
 
The digital images were anterior views of patients in the standing position from the neck to the 
umbilicus showing both breasts. Each digital image was scored as excellent, good, fair, poor or not 
suitable for analysis (due to poor image quality, both breasts not wholly visible, significant oncoplastic 
intervention, or mastectomy at the 3-year evaluation).  A spreadsheet with scores was returned to TROG 
staff for analyses. Analyses excluded subjects with missing or unsuitable images. 
 
To assess reproducibility of the single-reviewer digital image scoring, 100 randomly selected, good 
quality images were reviewed twice within the first 1000 images assessed.  The twice-reviewed images 
included baseline and 3-year post RT images with treating centre scores ranging from excellent to poor.   
A priori, the BIG 3-07/TROG 07.01 Steering Committee decided that the single-reviewer approach would 
be considered sufficiently consistent if the weighted Kappa statistic was ≥ 0.7 for a dichotomised 
endpoint (excellent/good vs. fair/poor).[19]  For the overall study, images of subjects with a change in 
score from excellent/good to fair/poor, or the converse, between baseline and 3-years post RT were re-
reviewed to approximate the use of average or consensus scores across multiple independent reviewers 
used in previous cosmetic analyses based on photo panels.[8,11,12,14] If necessary, scores were 
adjusted for one, neither or both images.  Final scores were used for analysis.    
 
Statistical analyses 
The centre-reported and digital image-reviewed global cosmetic scores were dichotomised as 
excellent/good (cosmetic success) vs. fair/poor (cosmetic failure).  Secondary analyses evaluated 
cosmetic outcome as a 4-part variable.  Cosmetic deterioration was a change from a score of 
excellent/good to fair/poor over time.  These definitions of cosmetic failure and deterioration have been 
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shown to be sensitive to patient, surgical and RT technical factors.[6-17]  To assess the single-reviewer 
consistency between initial and repeat scores and agreement between site reported and single reviewer 
scores, weighted kappa statistics were calculated ,. 
 
To assess international BCS cosmesis, baseline cosmetic scores were tabulated by four geographically-
defined clusters of treatment centres: Australasia (Australia, New Zealand and Singapore); Canada; the 
United Kingdom and Ireland; and the rest of Europe.  The purpose of geographic clustering was to 
balance sample size and potential ethnic or cultural influences.  Rates of excellent/good scores and the 
proportions of subjects with each 4-part score were compared by chi-squared tests and Kruskal-Wallis 
tests, respectively, between geographic regions using centre-reported EORTC scores and digital image 
scores.  Logistic regression was used to assess scores between geographic regions using both scoring 
methods. The impact of WBI dose-fractionation and TBB use were similarly evaluated using both scores 
across all subjects at the two time-points which included patients who may have either deteriorated or 
improved from baseline to the 3-year assessment.  Assessments included adjustment for region when 
examining baseline scores and both region and baseline score when examining 3-year outcomes by WBI 
fractionation and TBB use.   
 
Assessment for cosmetic deterioration involved only subjects with evaluable scores or images at both 
the baseline and 3-year time points.  The proportion of subjects with an excellent/good score at baseline 
who had a fair/poor score at three years post RT, using logistic regression to assess the impact of WBI 
dose-fractionation and TBB use, adjusted for geography and WBI approach (randomized or centre-
selected dose-fractionation).  Secondary analyses evaluated the proportion of subjects with fair/poor 
scores at baseline who had excellent/good scores at three years.    P<0.05 was considered statistically 
significant. Analyses were conducted in SAS version 9.4. 
 
Conduct of the BIG 03-07/TROG 07.01 trial 
The trial protocol was approved by the relevant committees of participating clinical trials groups and the 
institutional research ethics review boards of participating centres.  All patients signed written informed 
consent prior to any study-related procedures. 
 
 
Results 
Between June 1, 2007 and June 30, 2014, 1608 subjects from 136 centres in 11 countries were recruited 
to the trial (Appendix A). 116 centres contributed cosmetic assessments by February 18, 2018. EORTC 
global cosmetic scores were recorded for 1543 patients (96%) at baseline, 1239 patients (77%) at 3 years 
post RT and 1227 (76%) patients at both evaluation points. Standardised digital images were evaluable 
for 1428 patients (89%) at baseline, 1034 patients (64%) at 3 years and 999 (62%) patients at both time 
points.  The distributions of patient and treatment characteristics are shown in Table 1. 
 
The use of the two protocol-specified WBI fractionation regimens varied between geographic regions: 
62% of subjects in Australasia had WBI fractionation determined by random allocation compared to 4% 
of subjects in Europe (excluding the UK/Ireland).  Including patients whose WBI fractionation was 
determined by randomisation or centre election, the proportions of patients who had hypofractionated 
WBI were 33%, 34%, 59% and 78% for subjects from Australasia, Europe (excluding UK/Ireland), 
UK/Ireland and Canada, respectively.  Overall, 831 (52%) subjects were treated with conventionally 
fractionationated WBI and 777 (48%) were treated with hypofractionated WBI.  Analyses of the 
cosmetic impact of WBI dose-fractionation were therefore adjusted for geography.  Three of 785 (0.4%) 
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subjects with completed post-treatment dosimetry quality assurance review had minor protocol 
deviations (3D point dose >110%-115%) and no patients had major dosimetry protocol deviations. 
 
When randomly selected digital images (57 baseline and 43 three-year images) among the first 1000 
images assessed, were reviewed twice using the dichotomous cosmetic endpoint, there was strong 
agreement (weighted kappa=0.81 [95% confidence interval (CI) 0.67, 0.96]). Thus, the single-reviewer 
digital image review process was declared to be sufficiently consistent for cosmetic endpoint 
assessments.   
 
There was fair agreement between the digital image review and centre-reported global cosmetic scores 
for 1419 subjects with both scores at baseline using a dichotomized endpoint (weighted kappa=0.39 
[95% CI 0.33, 0.46]) and using the 4-part cosmetic outcome endpoint (weighted kappa=0.31 [95% CI 
0.26, 0.35]) as detailed in Appendix E.  For the 1003 subjects with both 3-year centre-reported global 
cosmetic scores and images available, the agreement was moderate for both the dichotomized endpoint 
(weighted kappa=0.47 [95% CI 0.39, 0.54]) and the 4-part cosmetic endpoint (weighted kappa=0.41 
[95% CI 0.36, 0.45]).  
 
There were no significant differences between the four geographic regions when cosmesis was 
evaluated as a dichotomized variable (Table 2). 85% to 90% (mean 88%) of subjects had excellent or 
good centre-reported global cosmetic scores at baseline (p=0.085). At baseline, there were no significant 
differences in the rate of excellent/good centre-reported EORTC scores by WBI fractionation received 
(87%-88%; p=0.80) or TBB use (87%-88%; p=0.91). Similar results were observed with the digital image 
scores as shown in Table 2.  
 
Using the four-part centre-reported global cosmetic scores, fewer subjects from Europe (excluding the 
UK/Ireland) were reported to have excellent cosmesis based on centre-reported global cosmetic scores 
(38% vs. 45%-56% excellent in other regions, p<0.001). However, this difference was not observed using 
the blinded, digital image review scores (49% excellent in Europe vs. 46%-52% excellent in other regions; 
p=0.17).  
Using centre-reported scores, excellent or good cosmesis was recorded for 88% of subjects at baseline 
and 84% of subjects at 3 years (p<0.0001, unadjusted and p<0.0001 adjusted for region, randomisation 
approach, TBB use and WBI dose-fractionation).  Similar results (84% at baseline and 81% at 3-years, 
p<0.0001, both unadjusted and adjusted) were observed using the digital image review global cosmetic 
scores.  The observed outcomes at three years included the potential for both deterioration and 
improvement in cosmesis over time. There were no significant differences in the proportions of subjects 
with excellent or good global cosmetic scores whether WBI dose-fractionation regimens were 
determined by centre selection or randomisation at baseline (87-88% excellent/good; p=0.29, adjusted 
for region) or at 3-years (82-86% excellent/good; p=0.68 adjusted for region and baseline score).  There 
were also no significant differences in the proportions of patients with excellent or good global cosmetic 
scores between the two WBI regimens used either at baseline (conventional fractionation 88% vs. 
hypofractionation 87%; p=0.72, adjusted for region) or at 3-years (conventional fractionation 83% vs. 
hypofractionation 85%; p=0.76, adjusted for region and baseline score).   In contrast, although the 
proportions of subjects with excellent or good centre-reported global cosmetic scores were similar 
between the TBB and no-TBB groups at baseline (87-88% excellent or good; p=0.92), patients 
randomized to receive a TBB had fewer excellent or good cosmetic scores at 3-years (TBB 80% vs. no-
TBB 88%; p<0.001, adjusted for WBI fractionation and baseline score).   
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Among 136 subjects with fair/poor baseline scores and available 3-year digital images, 38 (28%) had 
excellent or good global cosmetic scores at three years after RT.  The cosmetic improvement was due to 
the resolution of significant haematoma, oedema or erythema observed on the baseline images.  Using 
centre-reported scores, 85 (57%) of 150 patients with fair or poor scores at baseline had excellent or 
good global cosmetic scores at 3-years after RT.  
 
Cosmetic deterioration was evaluated among subjects with excellent or good scores at baseline and 
evaluable scores at both time points.  Of the 1227 subjects with both baseline and 3-year centre-
reported global cosmetic scores, 1077 (88%) had an excellent/good score at baseline.  Of the 999 
subjects with usable digital images at both baseline and 3 years, 863 (86%) had an excellent/good 
cosmetic score at baseline. Subjects who received a TBB were more than twice as likely to experience 
cosmetic deterioration from excellent/good to fair/poor at 3-years (odds ratio 2.04; 95% CI 1.39, 2.98; 
p<0.001 using centre-reported global cosmetic scores, and 2.82; 95% CI 1.76, 4.50; p<0.001 using the 
digital image review scores) as shown in Table 3.  Using the digital image scores, among subjects with 
excellent/good scores at baseline, 6% of patients in the no-TBB group and 16% who received a TBB had 
fair/poor scores at 3 years.   The adverse impact of TBB was similar whether the WBI was delivered with 
conventional or hypofractionation.  The p-values for interaction between WBI fractionation and TBB use 
were 0.57 using centre-reported and 0.30 using the digital image review global cosmetic scores. 
 
The rates of cosmetic deterioration did not differ between the two WBI regimens.  Eleven to 13% of 
subjects with excellent/good scores at baseline had fair/poor scores at 3 years depending on the 
cosmetic assessment method used and whether the subject received conventional or hypofractionated 
WBI (Table 4).  The odds ratios for cosmetic deterioration comparing conventional WBI to 
hypofractionated WBI were 1.06 (95% CI 0.72, 1.57; p=0.76) using centre-reported scores, and 1.40 (95% 
CI 0.85, 2.28; p=0.18] using digital image assessment scores.   
 
 
Discussion 
This is the first international study of cosmesis in patients with non-low risk DCIS treated by BCS and 
post-operative RT.  Cosmetic outcomes after BCS were comparable across 11 countries on four 
continents. Our study also demonstrated that hypofractionated WBI achieved statistically equivalent 
cosmetic outcomes compared to conventionally fractionated WBI, validating the findings of two large 
randomised trials conducted among women with invasive breast cancer.[9,10]  The use of a 16 Gy in 8 
fractions TBB was associated with a significantly increased risk of cosmetic deterioration as was shown 
in another study which tested the same boost dose in women with invasive breast cancer.[14]  Only 13% 
of patients received adjuvant endocrine therapy and no patient received chemotherapy. Thus, the 
findings of this study largely reflect the impact of local therapies alone.   
 
An EORTC randomised trial showed that a TBB of 16 Gy in 8 fractions improved local control for patients 
with invasive breast cancer,[20] but was associated with worse cosmesis in a proportion of 
patients.[8,14]  The same TBB added to a reduced whole breast dose of 45 Gy was not associated with 
worse cosmesis [21] and  a TBB of 10 Gy in four fractions resulted in a local recurrence odds reduction 
with overlapping confidence intervals compared to the EORTC study but with no difference in patient-
reported cosmesis.[22]  The 10 Gy in four fraction boost regimen may be a pragmatic way to achieve the 
therapeutic benefits of a TBB while minimising the associated adverse effects and treatment 
inconvenience. The efficacy of TBB to improve local control in patients with DCIS is the primary endpoint 
of BIG 03-07/TROG 07.01, and will be analysed five years after the end of accrual. 
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In this study of patients with DCIS, approximately 10-15% had fair or poor cosmesis at baseline after 
BCS, independent of geography.  This was similar to the rates of cosmetic failure after BCS among 
patients with invasive breast cancer dating to the 1980s.[6-11,15,17]  Cosmetic failure has been 
associated with various patient and treatment factors.  In particular, breast cosmesis is strongly 
impacted by the volume of breast tissue and/or skin resected and wound closure techniques which 
impact the size and shape of the treated breast, and the location and orientation of the nipple-areolar 
complex.  Since DCIS does not involve the skin, it is concerning to observe that some of these adverse 
effects of BCS were not ameliorated compared to BCS practices from several decades earlier.  The use of 
onco-plastic surgery was not prospectively recorded in our trial database but during digital image 
review, only a small number of patients were observed to have had such procedures on one or both 
breasts.   
 
The use of hypofractionated WBI in our study was much more common in Canada and the UK/Ireland 
compared to Australasia or the rest of Europe.  This finding is consistent with the long-standing practice 
of using hypofractionation for early-stage invasive breast cancer and the successful conclusion of large 
clinical trials of breast RT fractionation conducted in the former jurisdictions.[9,10,17]  The clinical trials 
of hypofractionated WBI for invasive breast cancer showed that the shorter fractionation was equally 
well tolerated compared to the more extended, conventional fractionation, and local control was similar 
or better with the shorter fractionation.[9,10]  There is also suggestive evidence that short fractionation 
is well tolerated when the regional lymph nodes are part of the treatment volume.[22,23]  A large UK 
trial evaluating whether WBI could be safely delivered in one week for invasive breast cancer has 
completed accrual and long-term data on the effects of this regimen on breast recurrence, fibrosis and 
cosmesis is awaited.[24]  Time to local recurrence is the primary endpoint of the BIG 03-07/TROG 07.01 
trial, and this pending result may help inform whether hypofractionated WBI could be considered a 
standard approach in patients with DCIS.   
 
Our study has confirmed that prospective collection of standardised clinical images could be used to 
evaluate the cosmetic effects of surgery and RT on the breast.   The cosmetic scoring of clinical images 
by a single reviewer, blinded to treatment, geography and timing was more internally consistent than 
when the digital image review scores were compared to treatment centre-reported scores.  The scoring 
of global cosmesis is subjective and it was interesting to note that centres in Europe were somewhat less 
likely to provide an excellent score compared to other jurisdictions.  In contrast, European centres did 
not have fewer excellent outcomes at baseline when the digital images were reviewed.  In the EORTC 
boost trial, use of a digitizer to quantify breast changes was reliable but unable to detect elements such 
as skin changes that might influence the global cosmetic interpretation from images.[8]  The single-
reviewer system was adopted due to availability of a reviewer with experience in the evaluation of 
breast cosmesis,[11,13,17] and the logistical complexity in a large, international trial, to assemble, train, 
demonstrate consistency between, and convene image panels in different countries to review images in 
a timely manner.  Whether similar results would be obtained by other single reviewers is unknown.  
Nonetheless, both the centre-reported and the digital image review processes were able to detect the 
adverse effects of a TBB on breast cosmesis.  It is interesting to note there were statistically fewer 
excellent centre-reported global cosmetic scores reported from centres in Europe compared to other 
geographic regions.  This was likely due to variation in the application of an excellent score as no 
differences in the rates of excellent global cosmetic scores were reported using the more internally 
consistent, single-reviewer system.    
 
A strength of our study is the large sample size contributed from 116 centres in 11 countries with 
consistent, prospective use of the validated EORTC Cosmetic Rating System.  The System entails an 
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assessment of nine parameters that contribute to the overall cosmetic outcome plus an explicit 
statement about the overall cosmetic appearance of the treated breast in comparison to the non-
treated breast.[18] The observed cosmetic results in the BIG 03-07/TROG 07.01 trial likely reflect real-
world outcomes in clinical practice.  
 
Our study had a number of limitations.  Not all patients had prospectively evaluated cosmetic scores or 
high-quality digital images available at both baseline and 3-years after RT.  This was in part related to 
follow-up duration at the time of the analysis, quality of the images, and the logistical challenges of 
timely submission of data and images from a large number of centres in an international trial.  However, 
our study is the largest prospective evaluation of cosmetic outcomes for women with DCIS and, pending 
the efficacy analysis, will provide robust data on the relative effects of TBB and WBI dose-fractionation 
on normal tissues and cosmetic outcomes. Patient perceptions of the outcomes of breast conserving 
therapies are important.  Analyses of patient reported outcomes collected prospectively as part of the 
BIG 03-07/TROG 07.01 trial will be reported separately. Since adverse cosmetic effects may progress 
over time, long-term follow up including cosmetic evaluations of study participants will be necessary to 
confirm the current observations. 
 
  
10 
 
References:   
1. Morrow M, Strom EA, Bassett LW, Dershaw DD, Fowble B, Giuliano A, et al. Standard for breast 
conservation therapy in the management of invasive breast carcinoma.  CA Cancer J Clin 
2002;52:277-300. 
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor 
C, Arriagada R, et al.  Effect of radiotherapy after breast-conserving surgery on 10-year 
recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 
women in 17 randomised trials. Lancet 2011;378:1707-16.  
3. Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM; PRIME II investigators. Breast-
conserving surgery with or without irradiation in women aged 65 years or older with early 
breast cancer (PRIME II): a randomised controlled trial.  Lancet Oncol 2015;16:266-73.  
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Correa C, McGale P, Taylor C, Wang 
Y, Clarke M, et al.  Overview of the randomized trials of radiotherapy in ductal carcinoma in situ 
of the breast. J Natl Cancer Inst Monogr 2010;41:162-77. 
5. Van Limbergen E, van der Schueren E, Van Tongelen K.  Cosmetic evaluation of breast 
conserving treatment for mammary cancer. 1. Proposal of a quantitative scoring system. 
Radiother Oncol 1987;8:1-9.  
6. Van Limbergen E, Rijnders A, van der Schueren E, Lerut T, Christiaens R. Cosmetic evaluation of 
breast conserving treatment for mammary cancer. 2. A quantitative analysis of the influence of 
radiation dose, fractionation schedules and surgical treatment techniques on cosmetic results. 
Radiother Oncol 1989;16:159-67. 
7. Rose MA, Olivotto I, Cady B, Koufman C, Osteen R, Silver B, et al. Conservative surgery and 
radiation therapy for early breast cancer. Long-term cosmetic results. Arch Surg 1989;124:153-7. 
8. Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JH, Jager JJ, et al.  The influence of 
patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in 
the EORTC 'boost vs. no boost' trial. Radiother Oncol 2000;55:219-32. 
9. Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, et al.  Long-term results of 
hypofractionated radiation therapy for breast cancer. N Engl J Med 2010;362:513-20. 
10. Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, et al.  The UK 
Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for 
treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. 
Lancet Oncol 2013;14:1086-94.  
11. Olivotto IA, Whelan TJ, Parpia S, Kim DH, Berrang T, Truong PT,  et al. Interim cosmetic and 
toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using 
three-dimensional conformal external beam radiation therapy. J Clin Oncol 2013;31:4038-45. 
12. Haviland JS, Hopwood P, Mills J, Sydenham M, Bliss JM, Yarnold JR, et al. Do patient-reported 
outcome measures agree with clinical and photographic assessments of normal tissue effects 
after breast radiotherapy? The experience of the Standardisation of Breast Radiotherapy 
(START) trials in early breast cancer.  Clin Oncol 2016;28:345-53.  
13. Olivotto IA, Rose MA, Osteen RT, Love S, Cady B, Silver B, et al. Late cosmetic outcome after 
conservative surgery and radiotherapy: analysis of causes of cosmetic failure.  Int J Radiat Oncol 
Biol Phys 1989;17:747-53.  
14. Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JC, Jager JJ, et al.  The influence of the 
boost in breast-conserving therapy on cosmetic outcome in the EORTC "boost versus no boost" 
trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for 
Research and Treatment of Cancer. Int J Radiat Oncol Biol Phys 1999;45:677-85. 
11 
 
15. Stanton AL, Krishnan L, Collins CA. Form or function? Part 1. Subjective cosmetic and functional 
correlates of quality of life in women treated with breast-conserving surgical procedures and 
radiotherapy.  Cancer 2001;91:2273-81. 
16. Krishnan L, Stanton AL, Collins CA, Liston VE, Jewell WR.  Form or function? Part 2. Objective 
cosmetic and functional correlates of quality of life in women treated with breast-conserving 
surgical procedures and radiotherapy.  Cancer 2001;91:2282-7.  
17. Olivotto IA, Weir LM, Kim-Sing C, Bajdik CD, Trevisan CH, Doll CM, et al.  Late cosmetic results of 
short fractionation for breast conservation. Radiother Oncol 1996;41:7-13.   
18. Aaronson NK, Bartelink H, van Dongen JA, van Dam FS. Evaluation of breast conserving therapy: 
Clinical, methodological and psychosocial perspectives. Eur J Surg Oncol 1988;14:133-40. 
19. Fleiss JL, Levin B, Paik MC. (2003), Statistical Methods for Rates and Proportions, Third Edition, 
New York: John Wiley & Sons. 
20. Bartelink H, Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J, et al.  Whole-breast 
irradiation with or without a boost for patients treated with breast-conserving surgery for early 
breast cancer: 20-year follow-up of a randomised phase 3 trial.  Lancet Oncol 2015;16:47-56.  
21. Hau E, Browne LH, Khanna S, Cail S, Chin Y, Clark C, et al. Radiotherapy breast boost with 
reduced whole-breast dose is associated with improved cosmesis: the results of a 
comprehensive assessment from the St George and Wollongong randomized boost trial. Int J 
Radiat Biol Phys 2012;82:682-9. 
Romestaing P, Lehingue Y, Carrie C, Coquard R, Montbarbon X, Ardiet JM, et al.  Role of a 10-Gy 
boost in the conservative treatment of early breast cancer: results of a randomized clinical trial 
in Lyon, France. J Clin Oncol 1997;15:963-8. 
22. Leong N, Truong PT, Tankel K, Kwan W, Weir L, Olivotto IA.  Hypofractionated nodal radiation 
therapy for breast cancer was not associated with increased patient-reported arm or brachial 
plexopathy symptoms.  Int J Radiat Oncol Biol Phys 2017;99:1166-72.  
23. Haviland JS, Mannino M, Griffin C, Porta N, Sydenham M, Bliss JM, et al. Late normal tissue 
effects in the arm and shoulder following lymphatic radiotherapy: Results from the 
UK START (Standardisation of Breast Radiotherapy) trials. Radiother Oncol 2018;126:155-62. 
24. Brunt AM, Wheatley D, Yarnold J, Somaiah N, Kelly S, Harnett A, et al.  Acute skin toxicity 
associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-
week regimen delivered in the UK FAST-Forward Trial.  Radiother Oncol 2016;120:114-8.  
 
 
Table 1.  Patient, disease and treatment characteristics 
 Total 
No. (%) 
Boost 
No. (%) 
No Boost 
No. (%) 
Total   [No.  (%)] 1608 (100%) 803 (100%) 805 (100%) 
Age (years) median (range) 58 (31 - 82) 57 (31 - 82) 58 (35 - 81) 
Age  
<50 years 
≥ 50 years 
268 ( 17% ) 
1340 ( 83% ) 
133 ( 17% ) 
670 ( 83% ) 
135 ( 17% ) 
670 ( 83% ) 
Nuclear grade 
Low 
Intermediate 
High 
Missing 
 
105 ( 7% ) 
600 ( 38% ) 
874 ( 55% ) 
29  
56 ( 7% ) 
316 ( 41% ) 
409 ( 52% ) 
22 
49 ( 6% ) 
284 ( 36% ) 
465 ( 58% ) 
7 
Tumour size (maximum 
dimension) 
≤1.0cm 
>1.0-≤1.5cm 
>1.5cm 
528 ( 33% ) 
281 ( 17% ) 
799 ( 50% ) 
288 ( 36% ) 
132 ( 16% ) 
383 ( 48% ) 
240 ( 30% ) 
149 ( 18% ) 
416 ( 52% ) 
Region 
Australasia 
Canada 
UK/Ireland 
Rest of Europe 
520 ( 32% ) 
300 ( 19% ) 
406 ( 25% ) 
382 ( 24% ) 
259 ( 32% ) 
149 ( 19% ) 
205 ( 25% ) 
190 ( 24% ) 
261 ( 32% ) 
151 ( 19% ) 
201 ( 25% ) 
192 ( 24% ) 
WBI dose/fx group 
Randomized for dose/fx 
Selected 50Gy/25fx 
Selected 42.5Gy/16fx 
503 ( 31% ) 
581 ( 36% ) 
524 ( 33% ) 
251 ( 31% ) 
290 ( 36% ) 
262 ( 33% ) 
252 ( 31% ) 
291 ( 36% ) 
262 ( 33% ) 
WBI dose/ fx used 
42.5Gy/16fx 
50Gy/25fx 
777 ( 48% ) 
831 ( 52% ) 
388 ( 48% ) 
415 ( 52% ) 
389 ( 48% ) 
416 ( 52% ) 
Planned Endocrine Therapy 
Yes 
No 
211 ( 13% ) 
1397 ( 87% ) 
105 ( 13% ) 
698 ( 87% ) 
106 ( 13% ) 
699 ( 87% ) 
*Australasia = Australia, New Zealand and Singapore 
No. = number; WBI=whole breast irradiation; fx = number of fractions or treatments 
  
Table 2:  Distribution of BASELINE cosmesis by geography, whole breast fractionation and boost use 
 
 Centre-reported EORTC scores Digital Image Review Scores 
 Ex/G 
No. (%) 
F/P 
No. (%) 
p Ex 
No. (%) 
Missing 
No. 
Ex/G 
No. (%) 
F/P 
No. (%) 
p Ex 
No. (%) 
Missing 
No. 
Total 1351 
(88) 
192  
(12) 
 766 
(50) 
65 1225 
(86) 
203  
(14) 
 703 
(49) 
180 
Geographic 
region 
     Australasia* 
     Canada 
     UK/Ireland 
     Rest of Europe 
 
 
455 (89) 
243 (86) 
358 (90) 
295 (85) 
 
 
59 (11) 
40 (14) 
39 (10) 
54 (15) 
 
0.085 
 
 
285 (55) 
126 (45) 
221 (56) 
134 (38) 
 
 
6 
17 
9 
33 
 
 
434 (88) 
219 (83) 
296 (85) 
276 (85) 
 
 
58 (12) 
45 (17) 
51 (15) 
49(15) 
 
0.22 
 
 
256 (52) 
127 (48) 
161 (46) 
159 (49) 
 
 
28 
36 
59 
57 
WBI dose/fx used 
       50Gy/25fx 
       42.5Gy/16fx 
 
696 (88) 
655 (87) 
 
97 (12) 
95 (13) 
0.80  
404 (51) 
362 (48) 
 
38 
27 
 
640 (88) 
585 (84) 
 
91 (12) 
112 (16) 
0.050  
369 (50) 
334 (48) 
 
100 
80 
Boost use 
        Boost 
        No Boost 
 
667 (88) 
684 (87) 
 
94 (12) 
98 (13) 
0.91  
383 (50) 
383 (49) 
 
42 
23 
 
607 (85) 
618 (86) 
 
105 (15) 
98 (14) 
0.57  
353 (50) 
350 (49) 
 
91 
89 
*Australasia = Australia, New Zealand and Singapore 
Ex/G=excellent or good cosmetic score; F/P=fair or poor cosmetic score; p=p-value; Ex=Excellent 
cosmetic score; No.=number; WBI=whole breast irradiation; fx=number of fractions or treatments; 
Gy=Gray; 
  
Table 3: Odds Ratios for cosmetic deterioration by boost use 
 
 Centre-reported EORTC scores Digital Image Review Scores 
 Ex/G at 
Baseline 
No. 
F/P at 
3 years 
No. (%) 
Odds 
Ratio* 
(95% CI) 
P* Ex/G 
Baseline 
No. 
F/P at 
3 years 
No. (%) 
Odds Ratio* 
(95% CI) 
P* 
Total 1077 132 (12)   863 94 (11)   
Boost use 
       Boost 
       No Boost 
 
538 
539 
 
86 (16) 
46 (9) 
2.04 
(1.39, 2.98) 
<0.001  
428 
435 
 
67 (16) 
27 (6) 
2.82 
(1.76, 4.50) 
<0.001 
         
*Odds Ratio for comparison Boost vs. No Boost, logistic regression adjusted for whole breast irradiation 
approach (dose randomized or centre-selected as conventional or short fractionation). 
Ex/G=Excellent or Good cosmetic score; F/P=Fair or Poor cosmetic score; No.=number; p=p-value;  
CI=confidence interval; WBI=whole breast irradiation; Gy=Gray; fx=fractions=number of treatments;  
  
Table 4: Odds Ratios for cosmetic deterioration by whole breast dose fractionation used 
 
 Centre-reported EORTC scores Digital Image Review Scores 
 Ex/G at 
Baseline 
No.  
F/P at 
3 years 
No. (%) 
Odds Ratio* 
(95% CI) 
P* Ex/G 
Baseline 
No. 
F/P at 
3 years 
No. (%) 
Odds Ratio* 
(95% CI) 
P* 
Total 1077 132 (12)   863 94 (11)   
WBI dose/fx used 
       50Gy / 25fx 
       42.5Gy / 16fx 
 
542 
535 
 
71 (13) 
61 (11) 
1.06  
(0.72, 1.57) 
0.76  
440 
423 
 
47 (11) 
47 (11) 
1.40 
(0.85,2.28) 
0.18 
*Odds Ratio for comparison 50Gy vs. 42.5Gy, logistic regression adjusted for geography. 
Ex/G=Excellent or Good cosmetic score; F/P=Fair or Poor cosmetic score; No.=number; p=p-value; 
CI=confidence Interval; WBI=whole breast irradiation; Gy=Gray; fx=fractions=number of treatments;  
 
 
